Clinical Trials

Clinical trials are research studies that test whether new medical treatments, devices or strategies  are safe and effective.

People who volunteer for clinical trials play an active role in their own health care, often gain access to experimental treatments, and help others by improving and advancing medical care.

At Providence Cancer Center, our scientists and physicians work closely together to make clinical trials a regular part of cancer care. Patients may take part in studies initiated by our translational researchers at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute, in addition to studies sponsored by the National Cancer Institute or pharmaceutical and biotechnology companies.

Our clinical trials team works directly with physicians to identify clinical trials appropriate for their patients’ specific stage of disease.

The goals of clinical research vary from trial to trial. Generally, they are designed to:

  • Improve prevention, early diagnosis and treatment of cancer
  • Discover whether a particular drug  or medical treatment is safe and effective
  • Advance the state of scientific and medical knowledge
  • Measure and improve the quality of life for patients and their families
Find cancer clinical trials available in Oregon in the list below. You may search by keyword or condition/disease, or browse using the page numbers and arrows. Find additional trials by using the search term “Oncology Multiple Tumor Sites". To learn more about a particular trial and qualification criteria, click the trial name and then the listed contact link, or talk with your physician.

For more information about clinical trials available through Providence Cancer Center, call 503-215-2614
Viewing Page 5 of 32 | Showing Results 21 - 25 of 156

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and...

Todd Crocenzi, M.D.
  • Oncology and Hematology Care Eastside

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of...

Todd Crocenzi, M.D.
  • Oncology and Hematology Care Eastside

Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase I Multiple Ascending Dose Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1)Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Infection.

The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the...

Todd Crocenzi, M.D.
  • Oncology and Hematology Care Eastside
Viewing Page 5 of 32 | Showing Results 21 - 25 of 156